

Laura C Coates Mb Chb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4672778/publications.pdf>

Version: 2024-02-01

233
papers

8,791
citations

61984

43
h-index

53230

85
g-index

242
all docs

242
docs citations

242
times ranked

4730
citing authors

#	ARTICLE	IF	CITATIONS
1	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	5.6	726
2	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
3	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 2489-2498.	13.7	389
4	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 251-265.e19.	1.2	362
5	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	5.6	312
6	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	3.4	264
7	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. <i>British Journal of Dermatology</i> , 2017, 177, 628-636.	1.5	226
8	Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. <i>Arthritis Care and Research</i> , 2010, 62, 965-969.	3.4	201
9	Psoriatic arthritis: state of the art review. <i>Clinical Medicine</i> , 2017, 17, 65-70.	1.9	198
10	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.9	194
11	Development of a preliminary composite disease activity index in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 272-277.	0.9	184
12	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	8.0	182
13	The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System (PsAMRIS): Definitions of Key Pathologies, Suggested MRI Sequences, and Preliminary Scoring System for PsA Hands. <i>Journal of Rheumatology</i> , 2009, 36, 1816-1824.	2.0	168
14	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018, 392, 2367-2377.	13.7	159
15	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. <i>British Journal of Dermatology</i> , 2020, 183, 628-637.	1.5	131
16	Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.5	130
17	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 291-304.	3.4	119
18	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	30.5	113

#	ARTICLE	IF	CITATIONS
19	Treatment guidelines in psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, i37-i46.	1.9	111
20	Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. <i>Arthritis Care and Research</i> , 2010, 62, 970-976.	3.4	110
21	Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 582-590.	0.9	105
22	Clinical management of psoriatic arthritis. <i>Lancet, The</i> , 2018, 391, 2285-2294.	13.7	96
23	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.0	93
24	The TICOPA protocol (Tight Control of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 101.	1.9	89
25	Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. <i>Journal of Rheumatology</i> , 2016, 43, 356-361.	2.0	89
26	Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments. <i>Journal of Rheumatology</i> , 2016, 43, 371-375.	2.0	87
27	The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. <i>Rheumatology</i> , 2013, 52, 1754-1757.	1.9	79
28	Is There Subclinical Synovitis in Early Psoriatic Arthritis? A Clinical Comparison With Grayâ€šScale and Power Doppler Ultrasound. <i>Arthritis Care and Research</i> , 2014, 66, 432-439.	3.4	79
29	MRI and ultrasonography for diagnosis and monitoring of psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 805-822.	3.3	76
30	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	3.4	73
31	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensusâ€šBased Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	5.6	72
32	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016, 12, 743-750.	8.0	71
33	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placeboâ€šControlled Study. <i>Arthritis Care and Research</i> , 2016, 68, 267-274.	3.4	69
34	The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) Is Reliable and Sensitive to Change: Results from an OMERACT Workshop. <i>Journal of Rheumatology</i> , 2011, 38, 2034-2038.	2.0	66
35	Brief Report: Reduced Joint Counts Misclassify Patients With Oligoarticular Psoriatic Arthritis and Miss Significant Numbers of Patients With Active Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 1504-1509.	6.7	60
36	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	0.9	59

#	ARTICLE	IF	CITATIONS
37	Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 358-362.	0.9	57
38	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. <i>Rheumatology and Therapy</i> , 2020, 7, 553-580.	2.3	54
39	Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. <i>British Journal of Dermatology</i> , 2020, 183, 638-649.	1.5	54
40	Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1591-1597.	0.9	52
41	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 36-47.	5.6	52
42	Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2014, 41, 2277-2285.	2.0	51
43	Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 359-369.	0.9	47
44	Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 251-257.	0.9	46
45	Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients. <i>Rheumatology and Therapy</i> , 2017, 4, 219-231.	2.3	44
46	Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2018, 5, 567-582.	2.3	43
47	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	2.0	43
48	Assessing Disease Activity in Psoriatic Arthritis: A Literature Review. <i>Rheumatology and Therapy</i> , 2019, 6, 23-32.	2.3	43
49	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B*27 Status?. <i>Arthritis Care and Research</i> , 2021, 73, 856-860.	3.4	43
50	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	2.0	42
51	New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. <i>British Journal of Dermatology</i> , 2016, 174, 1174-1178.	1.5	39
52	Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study. <i>Arthritis Care and Research</i> , 2018, 70, 1529-1535.	3.4	39
53	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	3.4	39
54	Treating to target in psoriatic arthritis: how to implement in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 640-643.	0.9	38

#	ARTICLE	IF	CITATIONS
55	Considerations for the definition of remission criteria in psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 786-796.	3.4	38
56	Systematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the GRAPPA. <i>Journal of Rheumatology</i> , 2014, 41, 2273-2276.	2.0	37
57	New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. <i>Rheumatology</i> , 2017, 56, kew390.	1.9	36
58	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	2.0	36
59	Development of a Disease Activity and Responder Index for Psoriatic Arthritis – Report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , 2014, 41, 782-791.	2.0	34
60	Patient Involvement in Outcome Measures for Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 418.	4.7	34
61	Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review. <i>Journal of Rheumatology</i> , 2008, 35, 1438-42.	2.0	33
62	The involvement of the spine in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S31-5.	0.8	33
63	Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1161-1173.	2.4	32
64	Disease measurement – enthesitis, skin, nails, spine and dactylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 659-670.	3.3	31
65	Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. <i>Arthritis Research and Therapy</i> , 2018, 20, 272.	3.5	30
66	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579.	2.7	30
67	Testing an OMERACT MRI Scoring System for Peripheral Psoriatic Arthritis in Cross-sectional and Longitudinal Settings. <i>Journal of Rheumatology</i> , 2009, 36, 1811-1815.	2.0	29
68	The Changing Face of Clinical Trials in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2017, 19, 21.	4.7	29
69	Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. <i>Arthritis Care and Research</i> , 2018, 70, 1198-1205.	3.4	29
70	Treat-to-target in PsA: methods and necessity. <i>RMD Open</i> , 2020, 6, e001083.	3.8	27
71	Current concepts and unmet needs in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 297-305.	2.2	26
72	Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: a cross-sectional study. <i>British Journal of Dermatology</i> , 2016, 175, 542-548.	1.5	25

#	ARTICLE	IF	CITATIONS
73	Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health and Quality of Life Outcomes, 2020, 18, 173.	2.4	25
74	Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD Open, 2017, 3, e000415.	3.8	24
75	Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1. RMD Open, 2017, 3, e000567.	3.8	24
76	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Research and Therapy, 2018, 20, 242.	3.5	24
77	Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity. BMC Rheumatology, 2018, 2, 24.	1.6	24
78	What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?. Journal of Rheumatology, 2019, 46, 38-42.	2.0	24
79	Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. Rheumatology, 2019, 58, 144-148.	1.9	24
80	Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry Study. Journal of Rheumatology, 2020, 47, 548-552.	2.0	24
81	Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?. Current Rheumatology Reports, 2018, 20, 71.	4.7	23
82	GRAPPA Treatment Recommendations: An Update from the GRAPPA 2013 Annual Meeting. Journal of Rheumatology, 2014, 41, 1237-1239.	2.0	22
83	Psoriatic arthritis: lessons from imaging studies and implications for therapy. Expert Review of Clinical Immunology, 2017, 13, 133-142.	3.0	22
84	Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. Seminars in Arthritis and Rheumatism, 2020, 50, 709-718.	3.4	22
85	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. Arthritis Care and Research, 2014, 66, 1410-1416.	3.4	21
86	A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis		

#	ARTICLE	IF	CITATIONS
91	Measurement properties of the minimal disease activity criteria for psoriatic arthritis. RMD Open, 2019, 5, e001002.	3.8	19
92	Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value. Journal of Rheumatology, 2019, 46, 160-165.	2.0	19
93	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet Rheumatology, The, 2021, 3, e270-e283.	3.9	19
94	Imaging in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. Journal of Rheumatology, 2010, 37, 448-452.	2.0	18
95	Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients. Rheumatology and Therapy, 2019, 6, 521-528.	2.3	18
96	Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Rheumatology, 2020, 59, 1495-1504.	1.9	18
97	The dynamics of response as measured by multiple composite outcome tools in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. Annals of the Rheumatic Diseases, 2017, 76, 1688-1692.	0.9	17
98	Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA). RMD Open, 2018, 4, e000606.	3.8	17
99	Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. Arthritis Research and Therapy, 2019, 21, 266.	3.5	17
100	Prevalence of Psoriatic Arthritis Patients Achieving Minimal Disease Activity in Real-world Studies and Randomized Clinical Trials: Systematic Review with Metaanalysis. Journal of Rheumatology, 2020, 47, 839-846.	2.0	17
101	Implementing the findings of the TICOPA trial in clinical practice: challenges in implementation and how information technology can bridge the gap. Clinical and Experimental Rheumatology, 2016, 34, S73-S74.	0.8	17
102	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. Annals of the Rheumatic Diseases, 2018, 77, e23-e23.	0.9	16
103	Remission in psoriatic arthritis—where are we now?. Rheumatology, 2018, 57, 1321-1331.	1.9	16
104	Gender equity in academic rheumatology: is there a gender gap at European rheumatology conferences?. RMD Open, 2022, 8, e002131.	3.8	16
105	Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: <sc>Threeâ€Year</sc> Results From a Phase <sc>Ib</sc> Randomized Controlled Trial and Its <sc>Openâ€Label</sc> Extension Study. Arthritis and Rheumatology, 2022, 74, 1959-1970.	5.6	16
106	Treat to Target in Psoriatic Arthritis—Evidence, Target, Research Agenda. Current Rheumatology Reports, 2015, 17, 517.	4.7	15
107	Outcome Measures in Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 699-710.	1.9	15
108	Psoriasis flare with corticosteroid use in psoriatic arthritis. British Journal of Dermatology, 2016, 174, 219-221.	1.5	15

#	ARTICLE	IF	CITATIONS
109	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. <i>Joint Bone Spine</i> , 2020, 87, 449-454.	1.6	14
110	GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201681.	2.0	14
111	A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action. <i>Joint Bone Spine</i> , 2021, 88, 105175.	1.6	14
112	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	2.0	14
113	Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. <i>Rheumatology</i> , 2019, 58, 1025-1033.	1.9	13
114	Mixed methods study of cliniciansâ€™ perspectives on barriers to implementation of treat to target in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1031-1036.	0.9	13
115	Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance. <i>Lancet Rheumatology</i> , The, 2021, 3, e28-e39.	3.9	13
116	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 1137-1147.	1.9	13
117	Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-blind Withdrawal Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1663-1672.	5.6	13
118	Cost-effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2018, 70, 462-468.	3.4	12
119	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 31-58.	0.7	12
120	Assessment of the many faces of PsA: single and composite measures in PsA clinical trials. <i>Rheumatology</i> , 2020, 59, i29-i36.	1.9	12
121	Comparing the Patient-reported Physical Function Outcome Measures in a Real-life International Cohort of Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 593-602.	3.4	12
122	GRAPPA Treatment Recommendations: Updates and Methods. <i>Journal of Rheumatology</i> , 2020, 96, 41-45.	2.0	12
123	GRAPPA Treatment Recommendations: 2021 Update. <i>Journal of Rheumatology</i> , 2022, , jrheum.211331.	2.0	12
124	GRAPPA Trainees Symposium 2009: A Report from the GRAPPA 2009 Annual Meeting: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 526-529.	2.0	11
125	Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1530-1534.	2.4	11
126	Measuring Outcomes in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 82-109.	3.4	11

#	ARTICLE	IF	CITATIONS
127	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001845.	3.8	11
128	Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence. <i>Rheumatology and Therapy</i> , 2022, 9, 803-821.	2.3	11
129	The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e66-e66.	0.9	10
130	Should Methotrexate Have Any Place in the Treatment of Psoriatic Arthritis?. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 325-339.	1.9	10
131	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 854-864.	2.0	10
132	Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial. <i>Journal of Rheumatology</i> , 2020, 47, 1338-1343.	2.0	10
133	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	2.0	10
134	A discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2967-2974.	2.2	9
135	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , 2021, 23, 94.	3.5	9
136	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021, , jrheum.201674.	2.0	9
137	Current treatments and recommendations for Psoriatic Arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101680.	3.3	9
138	Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab. <i>Rheumatology</i> , 2019, 58, 522-526.	1.9	8
139	Long-term follow-up of patients in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Rheumatology</i> , 2020, 59, 807-810.	1.9	8
140	Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. <i>Lancet Rheumatology</i> , The, 2022, 4, e262-e273.	3.9	8
141	Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 703-705.	2.0	7
142	FRI0509...Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from opal balance, an open-label, long-term extension study. , 2017, , .		7
143	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019, 95, 54-57.	2.0	7
144	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , 2020, 96, 53-57.	2.0	7

#	ARTICLE	IF	CITATIONS
145	Letâ€™s Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 970-973.	2.0	6
146	The Role of Ultrasound in Psoriatic Arthritis â€” Do We Need a Score?. <i>Journal of Rheumatology</i> , 2019, 46, 337-339.	2.0	6
147	Treatmentâ€™s Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. <i>Arthritis Care and Research</i> , 2020, 72, 814-821.	3.4	6
148	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1158-1181.	3.4	6
149	JAK1 selective inhibitors for the treatment of spondyloarthropathies. <i>Rheumatology</i> , 2021, 60, ii39-ii44.	1.9	6
150	How Should We Measure Peripheral Spondyloarthritis?. <i>Journal of Rheumatology</i> , 2022, 49, 239-241.	2.0	6
151	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. <i>Rheumatology</i> , 2022, 61, e255-e266.	1.9	6
152	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. <i>Rheumatology</i> , 2023, 62, 606-616.	1.9	6
153	Interleukin-17 inhibition in psoriatic arthritis. <i>Lancet</i> , The, 2015, 386, 1114-1116.	13.7	5
154	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 58-66.	2.0	5
155	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysisâ€”Correction. <i>Journal of Investigative Dermatology</i> , 2021, 141, 177-181.	0.7	5
156	Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritisâ€”study protocol for the MONITOR-PsA study, a trials within cohorts study design. <i>Trials</i> , 2021, 22, 185.	1.6	5
157	The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database. <i>Journal of Rheumatology</i> , 2018, 94, 26-29.	2.0	5
158	Best-practice Indicators in Psoriatic Disease Care. <i>Journal of Rheumatology</i> , 2019, 95, 38-45.	2.0	5
159	Comparing the Visual Analog Scale and the Numerical Rating Scale in Patient-reported Outcomes in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 836-840.	2.0	5
160	Psoriatic arthritis: An up to date overview. <i>Indian Journal of Rheumatology</i> , 2020, 15, 45.	0.4	5
161	FRIO463â€¦Secukinumab Improves Minimal Disease Activity Response Rates in Patients with Active Psoriatic Arthritis: Data from The Randomized Phase 3 Study, Future 2. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 605.1-605.	0.9	4
162	International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 684-685.	2.0	4

#	ARTICLE	IF	CITATIONS
163	Personalized medicine “a new reality in psoriatic arthritis?. Nature Reviews Rheumatology, 2018, 14, 449-451.	8.0	4
164	Precision medicine in psoriatic arthritis: how should we select targeted therapies?. Lancet Rheumatology, The, 2019, 1, e66-e73.	3.9	4
165	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology, 2021, 60, 1588-1592.	1.9	4
166	Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. Journal of Rheumatology, 2021, 48, 1268-1271.	2.0	4
167	What“influences patients“™ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. Rheumatology, 2021, 60, 5292-5299.	1.9	4
168	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. Seminars in Arthritis and Rheumatism, 2021, 51, 1117-1124.	3.4	4
169	Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study. Rheumatology Advances in Practice, 2021, 5, rkab076.	0.7	4
170	Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Research and Therapy, 2022, 24, 40.	3.5	4
171	Psoriatic arthritis: prospects for the future. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210867.	2.7	4
172	Treat-to-target in psoriatic arthritis“ cost-effective in the biosimilar era. Lancet Rheumatology, The, 2022, 4, e390-e391.	3.9	4
173	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. RMD Open, 2022, 8, e002031.	3.8	4
174	Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results. Clinical Rheumatology, 2022, 41, 3035-3047.	2.2	4
175	Summary of the International Federation of Psoriasis Associations (IFPA) Meeting: A Report from the GRAPPA 2009 Annual Meeting. Journal of Rheumatology, 2011, 38, 530-539.	2.0	3
176	GRAPPA 2015 Research and Education Project Reports. Journal of Rheumatology, 2016, 43, 979-985.	2.0	3
177	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. Rheumatology Advances in Practice, 2020, 4, rkaa032.	0.7	3
178	Performance and Predictors of Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated With Adalimumab. Arthritis Care and Research, 2020, , .	3.4	3
179	Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. Journal of Rheumatology, 2021, , jrheum.201675.	2.0	3
180	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 1547-1551.	2.0	3

#	ARTICLE	IF	CITATIONS
181	Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey. <i>Rheumatology and Therapy</i> , 2021, 8, 1741-1758.	2.3	3
182	GRAPPA 2017 Project Report. <i>Journal of Rheumatology</i> , 2018, 94, 48-51.	2.0	3
183	The state of the art of psoriatic arthritis outcome assessment in clinical trials and daily practice. <i>Lancet Rheumatology</i> , The, 2022, 4, e220-e228.	3.9	3
184	Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: a cross-sectional analysis. <i>Joint Bone Spine</i> , 2022, , 105372.	1.6	3
185	Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study. <i>Patient</i> , 0, , .	2.7	3
186	SAT0305 of MDA criteria for PSA show good correlation with physician and patient opinions and with proposed composite measures. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 575.2-575.	0.9	2
187	GRAPPA 2016 Project Report. <i>Journal of Rheumatology</i> , 2017, 44, 706-710.	2.0	2
188	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2021, , jrheum.201679.	2.0	2
189	P184 of Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial. <i>Rheumatology</i> , 2021, 60, .	1.9	2
190	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 367-386.	3.4	2
191	How should we define disease and outcomes in axial psoriatic arthritis?. <i>Lancet Rheumatology</i> , The, 2021, 3, e677-e678.	3.9	2
192	Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 40-43.	2.0	2
193	SAT0556 of Methotrexate Efficacy in Early Psoriatic Arthritis of Open Label Data from the Ticopa Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 861.2-861.	0.9	1
194	THU0426 of Ultrasound Identifies Additional Erosive Disease in Patients with Early Psoriatic Arthritis of Results from the Ticopa Study:. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 353.1-353.	0.9	1
195	Patient education and screening for psoriatic arthritis is key in the care of patients with psoriasis, whichever method is chosen. <i>British Journal of Dermatology</i> , 2017, 176, 574-575.	1.5	1
196	An educational leaflet improves response to invitation for screening for arthritis in patients with psoriasis in primary care, but only in practices in the most deprived areas. <i>Clinical Rheumatology</i> , 2017, 36, 719-723.	2.2	1
197	SAT0469 of Integrated efficacy analysis of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis. , 2017, , .		1
198	SAT0464 of The ideal target for psoriatic arthritis? comparison of remission and inactive disease states in a real life cohort. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
199	How routine use of a treat to target approach in PsA might impact on clinical decision making. <i>Rheumatology</i> , 2018, 57, 209-210.	1.9	1
200	AB0741â€¦ACHIEVEMENT OF CDAPSA LOW DISEASE ACTIVITY OR REMISSION IS ASSOCIATED WITH CONTROL OF ARTICULAR AND EXTRA-ARTICULAR MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN SUBJECTS TREATED WITH APREMILAST. , 2019, , .		1
201	Measuring Physical Function in Psoriatic Arthritis: Comparing the Multidimensional Health Assessment Questionnaire to the Health Assessment Questionnaireâ€™Disability Index. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.200927.	2.0	1
202	Impact of Psoriatic Disease on Women Aged 18â€™45: Results from a Multinational Survey across 11 European Countries. <i>International Journal of Women's Dermatology</i> , 2021, 7, 697-707.	2.0	1
203	To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery?. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab057.	0.7	1
204	Paradigms of Treatment in PsA. , 2016, , 243-252.		1
205	Psoriatic arthritis in developing and resource-poor countries. <i>Lancet Rheumatology</i> , The, 2020, 2, e200-e202.	3.9	1
206	Therapy strategies in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S70-2.	0.8	1
207	Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2022, , jrheum.211322.	2.0	1
208	Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis. <i>British Journal of Dermatology</i> , 2022, , .	1.5	1
209	Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey. <i>Rheumatology and Therapy</i> , 2022, 9, 823-838.	2.3	1
210	OA33â€™fThe top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership. <i>Rheumatology</i> , 2022, 61, .	1.9	1
211	SAT0406â€™Low Level of Erosive Change is Found in Early Psoriatic Arthritis:. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 741.2-742.	0.9	0
212	069.â€™fCONSTRUCT VALIDITY, RESPONSIVENESS AND MINIMALLY IMPORTANT DIFFERENCE OF THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 IN PSORIATIC ARTHRITIS. <i>Rheumatology</i> , 2017, 56, .	1.9	0
213	A new era for collaboration?. <i>Rheumatology</i> , 2018, 57, 775-776.	1.9	0
214	Response to: â€™To DAPSA or not to DAPSA? That is not the question' by Schoels <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e62-e62.	0.9	0
215	255â€™fSecukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two Phase 3 studies, FUTURE 2 and FUTURE 3. <i>Rheumatology</i> , 2019, 58, .	1.9	0
216	AB0737â€™ACHIEVEMENT OF RAPID3 NEAR REMISSION OR LOW SEVERITY IS ASSOCIATED WITH RESIDUAL LEVELS OF ARTICULAR AND EXTRA-ARTICULAR MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN SUBJECTS TREATED WITH APREMILAST. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
217	FRI0429â€¦NON TOPICAL PHARMACOLOGICAL TREATMENT OF EARLY, UNTREATED (DMARD-NAËVE, SYSTEMIC) Tj ETQq1 0 0.7843		
218	Neue Ansätze beim Management der Psoriasis-Arthritis: Können wir zielgerichtet behandeln?. Karger Kompass Autoimmun, 2019, 1, 8-16.	0.0	0
219	BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. Rheumatology Advances in Practice, 2020, 4, rkaa043.	0.7	0
220	Treat to target in PsA should focus on clinical measures. Response to: â€DAPSA versus cDAPSA: do we need to use CRP?â€™ by GonÅšalves et al. Annals of the Rheumatic Diseases, 2020, 79, e143-e143.	0.9	0
221	The road to personalised medicine in psoriatic arthritis. Expert Review of Clinical Immunology, 2021, 17, 799-802.	3.0	0
222	Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores. Clinical Trials, 2021, 18, 541-551.	1.6	0
223	THU0314â€¦Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials. , 2018, , .		0
224	THU0284â€¦Haq in psoriatic arthritis is driven by gender, inflammation and ageing: observational data from cohort studies in uk, denmark, iceland and sweden. , 2018, , .		0
225	Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2110576.	2.7	0
226	Young-GRAPPA at the Annual GRAPPA Meeting: Presentation of a New Group Within GRAPPA and Its Vision. Journal of Rheumatology, 2022, , jrheum.211327.	2.0	0
227	P257â€fAre there regional variations in access to biological disease modifying anti-rheumatic drugs for the treatment of psoriatic arthritis in England?. Rheumatology, 2022, 61, .	1.9	0
228	P258â€fSecukinumab Improves Physical Function and Inhibits Structural Damage in Psoriatic Arthritis PsA Patients With Sustained Remission or Low Disease Activity: Results From a Phase 3 Study. Rheumatology, 2022, 61, .	1.9	0
229	P260â€fSecukinumab in Patients With Psoriatic Arthritis and Axial Manifestations: Predictors of Response From the Double-blind, Randomised, Phase 3b MAXIMISE Trial. Rheumatology, 2022, 61, .	1.9	0
230	P273â€fFactors related to insomnia in patients with psoriatic arthritis: a cross-sectional study. Rheumatology, 2022, 61, .	1.9	0
231	OA36â€fBimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study. Rheumatology, 2022, 61, .	1.9	0
232	P266â€fSecukinumab provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of five phase 3 studies. Rheumatology, 2022, 61, .	1.9	0
233	The need for clarity on the use of glucocorticoids for people with psoriatic arthritis: A call for consensus. Rheumatology, 0, , .	1.9	0